A Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155) (CTMS# 16-0009)
Objective: In both the Dose Evaluation and Signal Detection phases, evaluate the safety
and tolerability of the treatment combination.
Objective: Within each disease type of the Signal Detection phase, evaluate objective
response rate (ORR) according to investigator assessment using the disease specific criteria.
Objective: To evaluate the Objective Response Rate (ORR; complete response [CR] +
partial response [PR]) of the combination of pembrolizumab and dinaciclib within each
disease type, ie, CLL based on iwCLL guidelines (Hallek, 2008) , MM based on
IMWG criteria (Durie, 2006)  and DLBCL based on the Revised Response Criteria for
Malignant Lymphoma (Cheson, 2007) .
Objective: Within each disease type of the Signal Detection phase, evaluate Duration of
Response (DOR), Progression-Free Survival (PFS) according to investigator assessment
using the disease specific criteria; and Overall Survival (OS).